Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

• Status: Completed
• Trial end date: 2007-10-01

Summary

The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis